{"id":"tp-51627","type":"article-newspaper","title":"Elutia Targets Q4 FDA Filing for Antibiotic-Coated NXT-41x Matrix","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/51627","datePublished":"2026-11-08T14:02:33.000Z","dateModified":"2026-11-08T14:02:33.000Z","language":"en","abstract":"CEO Dr. Randy Mills projected a clearance decision in Q2 2027, within Elutia's broader first-half target. The reported antibacterial results came from a rabbit study.","section":"Business","references":[]}